Gene · 2050
Papers2,238
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 2,238
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma. | Int J Mol Sci | 2022 | 36555090 | PubTator, text mining | PubMed |
| An Investigation of the Etiologies of Non-Immune Hydrops Fetalis in the Era of Next-Generation Sequence-A Single Center Experience. | Genes (Basel) | 2022 | 36553497 | PubTator, text mining | PubMed |
| Eph/Ephrin Promotes the Adhesion of Liver Tissue-Resident Macrophages to a Mimicked Surface of Liver Sinusoidal Endothelial Cells. | Biomedicines | 2022 | 36551990 | PubTator, text mining | PubMed |
| Vascular lesions of the pediatric orbit: A radiological walkthrough. | Front Pediatr | 2022 | 36533238 | PubTator, text mining | PubMed |
| Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report. | Front Oncol | 2022 | 36531025 | PubTator, text mining | PubMed |
| Molecular models of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms. | Nat Commun | 2022 | 36509784 | PubTator, text mining | PubMed |
| Brain arteriovenous malformation in hereditary hemorrhagic telangiectasia: Recent advances in cellular and molecular mechanisms. | Front Hum Neurosci | 2022 | 36504622 | PubTator, text mining | PubMed |
| EPH/Ephrin-Targeting Treatment in Breast Cancer: A New Chapter in Breast Cancer Therapy. | Int J Mol Sci | 2022 | 36499598 | PubTator, text mining | PubMed |
| The Dual Role of PDCD10 in Cancers: A Promising Therapeutic Target. | Cancers (Basel) | 2022 | 36497468 | PubTator, text mining | PubMed |
| Sourcing cells for in vitro models of human vascular barriers of inflammation. | Front Med Technol | 2022 | 36483299 | PubTator, text mining | PubMed |
| Whole genome sequencing identifies structural variants contributing to hematologic traits in the NHLBI TOPMed program. | Nat Commun | 2022 | 36481753 | PubTator, text mining | PubMed |
| Ephrin-B2-expressing natural killer cells induce angiogenesis. | JVS Vasc Sci | 2022 | 36439700 | PubTator, text mining | PubMed |
| Biochemical Targets and Molecular Mechanism of Ginsenoside Compound K in Treating Osteoporosis Based on Network Pharmacology. | Int J Mol Sci | 2022 | 36430397 | PubTator, text mining | PubMed |
| The Role of Cluster C19MC in Pre-Eclampsia Development. | Int J Mol Sci | 2022 | 36430313 | PubTator, text mining | PubMed |
| The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors. | Cell Commun Signal | 2022 | 36419156 | PubTator, text mining | PubMed |
| Capillary Malformation-Arteriovenous Malformation Syndrome Due to EPHB4 Gene Mutation: Clinical, Dermoscopic, Ecographic and Histopathological Features. | Indian J Dermatol | 2022 | 36386110 | PubTator, text mining | PubMed |
| An ErbB Lineage Co-Regulon Harbors Potentially Co-Druggable Targets for Multimodal Precision Therapy in Head and Neck Squamous Cell Carcinoma. | Int J Mol Sci | 2022 | 36362284 | PubTator, text mining | PubMed |
| Genomic and Immune Approach in Platinum Refractory HPV-Negative Head and Neck Squamous Cell Carcinoma Patients Treated with Immunotherapy: A Novel Combined Profile. | Biomedicines | 2022 | 36359251 | PubTator, text mining | PubMed |
| Metabolomic, Lipidomic, Transcriptomic, and Metagenomic Analyses in Mice Exposed to PFOS and Fed Soluble and Insoluble Dietary Fibers. | Environ Health Perspect | 2022 | 36331819 | PubTator, text mining | PubMed |
| A new cell-free therapeutic strategy for liver regeneration: Human placental mesenchymal stem cell-derived extracellular vesicles. | J Tissue Eng | 2022 | 36313857 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2050/papers?page=19